FDA clears Biosense Websters EP imaging technology

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

The FDA has cleared for marketing Biosense Webster’s Carto 3 system, its 3D imaging technology, for use by electrophysiologists (EP) in treating cardiac arrhythmias.

The CARTO 3 system offers: advanced catheter location (ACL) technology, fast anatomical mapping (FAM), and a workflow feature called Connection of Choice.

According to the Diamond Bar, Calif.-based company:

  • ACL is a hybrid technology that allows for catheter tip and curve visualization without spatial distortion. The system can visualize up to five catheters simultaneously with distinction of electrodes.
  • FAM is a technology that creates high-resolution, CT-like maps, and also permits detailed visual enhancement of areas of interest within the heart.
  • Connection of Choice is enabled by the new Carto System hardware configuration featuring a central connection point for catheters and equipment while preserving the signal quality of intracardiac electrograms.